Eton Pharmaceuticals (ETON) Q2 2026 Earnings Call: Revenue Up 99%, Guidance Raised
Source Tradingkey
Key Takeaways
- Q2 2026 revenue increased 99% year over year to a record $37.6 million, led by the Hemangiol relaunch and growth across Increlex, the adrenal franchise, Galzin and carglumic acid.
- Adjusted EBITDA rose to $16.2 million, or 43% of revenue, from $3.1 million, or 16% of revenue, in Q2 2025. GAAP net income reached $11.6 million, or $0.35 per diluted share.
- Management raised full-year 2026 revenue guidance to more than $145 million from more than $120 million. Expected adjusted EBITDA margin increased to above 35% from above 30%.
- Hemangiol became Eton’s largest product following its May 1 relaunch. Approximately 95% of patients had transitioned to Eton Cares by the end of June, and management said the transition is now complete.
- Eton licensed ASN001, a late-stage topical treatment candidate for infantile hemangiomas. The company plans a 24-patient bioavailability study and expects to submit an NDA in the second half of 2027, potentially supporting a 2028 launch.
- Eton ended the quarter with $26.8 million in cash after a $3 million debt prepayment. The company plans to prioritize accretive product acquisitions while accelerating repayment of its remaining credit facility over the next six to 12 months.
Key Financial Data
| Metric | Q2 2026 | Q2 2025 | Change / Commentary |
|---|---|---|---|
| Revenue | $37.6 million | $18.9 million | Up 99% year over year |
| Gross profit | $25.4 million | $11.9 million | Up 113% |
| Adjusted gross profit | $27.4 million | $14.1 million | Adjusted margin was 73% versus 75% |
| R&D expense | $1.0 million | $3.7 million | Prior-year period included a Desmoda FDA filing fee |
| G&A expense | $11.6 million | $9.7 million | Up 20% |
| Adjusted EBITDA | $16.2 million | $3.1 million | Margin expanded to 43% from 16% |
| GAAP net income | $11.6 million | $(2.6) million | Diluted EPS of $0.35 versus a loss of $0.10 |
| Non-GAAP net income | $14.3 million | $1.5 million | Diluted EPS of $0.43 versus $0.03 |
| Cash at quarter-end | $26.8 million | — | After a $3 million debt prepayment |
Business and Operating Performance
Hemangiol and pediatric dermatology
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Recommended Articles
Oil prices surged 5% following direct Israel-Iran strikes, while gold tumbled below $4,300 as a blowout U.S. jobs report fueled intense market anxieties over a December Federal Reserve rate hike.
XRP (XRP) price trades near $1.05, caught between a year-long downtrend and a sudden burst of buying.July has historically rewarded XRP holders. This year the month arrives with on-chain accumulation
On July 1, Eastern Time, U.S. stocks closed fluctuating lower on the first trading day of the second half of the year. Although some megacap tech stocks such as Meta (
Gold holds above $4,350 following weak US jobs data. As inflation reports approach and UBS eyes $5,000, can XAUUSD break resistance at $4,435 to rally toward $4,500?
Gold Price Analysis Today: Gold Drops 1.32% Despite Lower Fed Rate-Hike Bets, Can $4,313 Support Hold?
Gold fell 1.32% on August 13 after rising to $4,449.73, then reversing lower and closing near $4,349.918 below the $4,356.46 support. Softer US inflation data reduced Fed rate hike expectations, but selling pressure still dominated the session. Will $4,313 support hold?
Gold fell 1.32% on August 13 after rising to $4,449.73, then reversing lower and closing near $4,349.918 below the $4,356.46 support. Softer US inflation data reduced Fed rate hike expectations, but selling pressure still dominated the session. Will $4,313 support hold?
